Abstract. Deregulation of microRNA (miRNA/miR) expression has been implicated in the development of pancreatic ductal adenocarcinoma (PDAC). However, the role of miR-661 in PDAC remains unknown. In the present study, it was revealed that miR-661 expression was significantly upregulated in PDAC tissues compared with that in adjacent normal tissues by using reverse transcription-quantitative polymerase chain reaction assays. Higher miR-661 expression revealed a positive association with lymph node metastasis, an advanced T stage and a poor prognosis in patients with PDAC. Furthermore, ectopic expression of miR-661 significantly promoted the cell proliferation ability in PDAC cell lines, and simultaneously promoted Wnt signaling pathway-related protein expression of β-catenin, transcription factor 4 and cyclin D1 in vitro. However, the downregulation of miR-661 revealed reverse effects. Thus, the results of the present study indicated that miR-661 may function as a prognostic marker and provide insight for pancreatic cancer treatment.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related mortality (1) . In 2016, there were an estimated 53,000 new cases and 42,000 cases of cancer-related mortality in the United States. The 5-year relative survival rate of PDAC is only 7% (2) . Due to the difficulty in diagnosing PDAC at an early stage, >50% of patients present with metastasis upon diagnosis (3) . Thus, investigating novel diagnostic markers and therapeutic targets for PDAC is critical.
MircroRNAs (miRNAs/miRs) are small and endogenous single-stranded RNA molecules. Previous studies revealed that miRNAs could bind to the 3'untranslated region of their target genes and regulate their post-transcriptional expression, which led to targeting the mRNA translational repression or degradation of genes (4, 5) . miRNAs have been shown to function as tumor suppressors or oncogenes in the development and progression of PDAC. Certain miRNAs, including miR-454 (6), miR-183-5p (7), miR-200a (8) and miR-138-5p (9) , have been reported to affect tumor cell proliferation, migration, invasion and metastasis.
miR-661 has been revealed to function as an oncogene in certain tumors, including breast cancer (10) , ovarian cancer (11) and non-small cell lung cancer (12) . However, the role of miR-661 in PDAC expression remains unknown. The present study aimed to reveal the clinical significance and functional effects of miR-661 on PDAC. The aim of the present study was to examine the expression of miR-661 in PDAC tissues and determine the association between miR-661 expression and poor prognosis of patients with PDAC. Furthermore, the effects of ectopic expression of miR-661 on proliferation of PDAC cells in vitro and the Wnt signalling pathway were examined. ). The RT-qPCR was performed using a TaqMan miRNA assay on an ABI7500 system (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The thermocycling conditions were as follows: Denaturation at 95˚C for 5 min followed by 35 cycles of denaturation at 95˚C for 15 sec and annealing/elongation at 60˚C for 30 sec. The relative mRNA expression was determined using the comparative 2 -ΔΔCq method (13) . The primer sequence for miR-661 was as follows: miR-661 forward: 5'-GTG CCT GGG TCT CTG GCC T-3'. U6 forward: 5'-CTC GCT TCG GCA GCA CA-3' and U6 reverse: 5'-AAC GCT TCA CGA ATT TGC GT-3'. The mRNA expression was normalized to U6.
Materials and methods

Tissue
Cell transfection. ASPC-1 and PANC-1 cells were transfected with 100 nM miRNA-negative control (miR-NC), miR-661 mimic (100 nM) or miR-661 inhibitor (100 nM) (Chang Jing Bio-Tech, Ltd., Changsha, China) using Lipofectamine ® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Following cell transfection for 48 h, the cells were harvested for RT-qPCR or western blot analysis to assess the mRNA and protein expression.
Cell proliferation assay. A cell proliferation assay was performed using Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology, Haimen, China). Briefly, a 96-well plate was seeded with ASPC-1 and PANC-1 cells (1x10 3 cells per well) and incubated for 24 h. Cells were transfected with miR-NC, miR-663 mimic or miR-663 inhibitor as aforementioned. Cell counting kit solution (10 µl) was added to each well according to the manufacturer's protocol, and cell proliferation was detected at 0, 1, 2 and 3 days. The cell proliferation was measured using a microplate spectrophotometer (Molecular Devices, LLC, Sunnyvale, CA, USA) at 450 nm.
Cell colony assay. ASPC-1 and PANC-1 cells (500 cells per well) were seeded in 6-well plates and cultured for 7 days. Cell colonies were fixed in 100% methanol at room temperature for 24 h and subsequently stained with 1% crystal violet at Table I . Association between miR-661 expression and clinical factors. 
Results
miR-661 expression is upregulated in PDAC tissues and is associated with a poor survival rate.
To determine the expression of miR-661 expression in PDAC tissues and adjacent normal tissues, RT-qPCR analyses were performed. As presented in Fig. 1A , PDAC tissues exhibited higher expression of miR-661 compared with adjacent normal tissues (P<0.05). In addition, the expression of miR-661 was higher in three human PDAC ASPC-1, PANC-1 and MIA PaCa-2 cell lines compared with that in the human pancreatic duct epithelial HPDE6 cell line (Fig. 1B) . To validate the association between miR-661 expression and clinical factors, the χ 2 test was performed. Results revealed that higher miR-661 expression demonstrated a positive association with lymph node metastasis (P<0.05; Figure 1 . miR-661 expression is upregulated in PDAC tissues and is associated with a poor survival rate. (A) miR-661 expression level in 59 paired PDAC tissues and corresponding adjacent normal tissues was examined with RT-qPCR. U6 was used as an internal control. (B) miR-661 expression level in three human PDAC ASPC-1, PANC-1 and MIA PaCa-2 cell lines and one human pancreatic duct epithelial HPDE6 cell line was examined via RT-qPCR. U6 was used as an internal control. (C) Kapan-Meier survival rate analysis revealed that the patients with higher miR-661 expression had a significantly worse disease-free survival (log-rank, 9.388; P<0.05) and (D) overall survival (log-rank, 9.629; P<0.05) rate than those with lower miR-661 expression. * P<0.05. miRNA/miR, microRNA; PDAC, pancreatic ductal adenocarcinoma; RT-qPCR, reverse transcription-quantitative polymerase chain reaction. Table I ) and advanced pathological T stage (P<0.05; Table I) in patients with PDAC. Kaplan-Meier survival analysis revealed that the patients with higher miR-661 expression had a significantly worse disease-free survival rate (log-rank, 9.388; P<0.05; Fig. 1C ) and overall survival rate (log-rank, 9.629; P<0.05; Fig. 1D ) than those with lower miR-661 expression.
Upregulation of miR-661 promotes proliferation of PDAC cell lines in vitro.
To investigate the effect of miR-661 expression on PDAC cell growth, gain of function and loss of function assays were performed in ASPC-1 and PANC-1 cells. The RT-qPCR analysis revealed that the miR-661 mimic caused an increase in miR-661 expression, while the miR-661 inhibitor caused a decrease in miR-661 expression in the ASPC-1 and PANC-1 cells (Fig. 2A) . The CCK-8 cell proliferation assays revealed that transfection of miR-661 mimic promoted cell proliferation in ASPC-1 and PANC-1 cells, whereas miR-661 inhibitor inhibited cell proliferation (Fig. 2B and C) . The results of cell colony formation assays revealed that transfection of miR-661 mimic in ASPC-1 and PANC-1 cells caused an increased cell colony number, whereas miR-661 inhibitor reduced the cell colony number (Fig. 2D and E) . These results indicated that upregulation of miR-661 promoted the cell proliferation capacity in vitro.
Upregulation of miR-661 activates the Wnt signaling pathway in vitro. The Wnt signaling pathway has been identified as an important regulating signalling pathway in PDAC (14) . To further confirm the regulatory association between miR-661 expression and the Wnt signaling pathway, the relative protein expressions of cyclin D1, TCF4 and β-catenin were detected. The results of the present study indicated that transfection of miR-661 mimic in PANC-1 cells caused an increase in protein expression of cyclin D1, TCF4 and β-catenin, whereas miR-661 inhibitor reduced the protein expression of cyclin D1, TCF4 and β-catenin in ASPC-1 cells (Fig. 3A and B) . Thus, these results indicated that upregulation of miR-661 could activate the Wnt signaling pathway in vitro.
Discussion
Understanding the molecular mechanisms underlying PDAC progression is important for investigating novel diagnostic markers and treatment targets (15) . miRNAs have emerged as a class of gene regulators involved in PDAC. For example, miR-545 inhibits PDAC growth by targeting retinoic acid-inducible gene-I (16). miR-337 regulates proliferation and invasion in PDAC by targeting homeobox protein B7 (HOXB7) (17) , and miR-429 exhibited a poor outcome in patients with PDAC and inhibits PDAC growth by targeting TANK-binding kinase 1 (18) . However, the role of miR-661 in PDAC progression remains unknown.
In the present study, it was revealed that miR-661 expression was significantly upregulated in PDAC tissues and cells. Higher miR-661 expression revealed a positive association with lymph node metastasis, an advanced T stage and a poor prognosis of patients with PDAC. Furthermore, ectopic expression of miR-661 significantly promoted cell proliferation in PDAC cells in vitro. These findings indicated that miR-661 may serve a tumor-promoting role in PDAC. Lower expression of miR-661 has been revealed in certain cancers in previous studies. For example, miR-661 contributed to the proliferation of human ovarian cancer cells by repressing inositol polyphosphate-5-phosphatase J expression (11) . miR-661 expression in SNAI1-induced epithelial-to-mesenchymal transition contributes to breast cancer cell invasion via targeting of nectin-1 and starD10 messengers (10) . miR-661 also promotes tumor cell invasion and metastasis by directly inhibiting retinoblastoma protein in non-small cell lung cancer (12) . Thus, the results of the present study indicated that miR-661 exhibited tumor proliferation promoting effects in PDAC.
Furthermore, the present study also demonstrated that transfection of the miR-661 mimic caused increased expression of TCF4 and β-catenin, whereas miR-661 inhibitor reduced the expression of TCF4 and β-catenin in PDAC cells. These results indicated that upregulation of miR-661 activated the Wnt signaling pathway in vitro. In a previous study, Wnt signaling was shown to serve a crucial role in pancreatic cancer progression; activation of Wnt/β-Catenin signaling enhanced pancreatic cancer development and the malignant potential via upregulation of cysteine-rich angiogenic inducer 61 (19) . The long non-coding RNA HOX transcript antisense RNA affects the radiosensitivity of PDAC by regulating the expression of Wnt inhibitory factor 1 (20) . The present study revealed that upregulation of miR-661 could activate the Wnt signaling pathway in vitro, which revealed the importance of miR-661 in PDAC progression.
In conclusion, the results of the present study revealed that miR-661 expression was higher in PDAC tissues and associated with prognosis. In vitro, miR-661 promoted cell proliferation and activated Wnt signaling. These results indicated that miR-661 may function as a prognostic biomaker and provide insight for the treatment of PDAC.
